

Edgar Lerma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2862630/publications.pdf>

Version: 2024-02-01

81
papers

4,436
citations

257450

24
h-index

106344

65
g-index

91
all docs

91
docs citations

91
times ranked

6048
citing authors

#	ARTICLE	IF	CITATIONS
1	Foreword. <i>Kidney International</i> , 2009, 76, S1-S2.	5.2	1,242
2	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619
3	Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2223.	7.4	319
4	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	5.2	235
5	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232
6	Prevalence of Atrial Fibrillation and Its Predictors in Nondialysis Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 173-181.	4.5	135
7	The Evolution of the Journal Club: From Osler to Twitter. <i>American Journal of Kidney Diseases</i> , 2017, 69, 827-836.	1.9	126
8	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 798-809.	4.5	124
9	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 760-773.	0.7	115
10	Class effects of SGLT2 inhibitors on cardiorenal outcomes. <i>Cardiovascular Diabetology</i> , 2019, 18, 99.	6.8	111
11	Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. <i>Kidney International Reports</i> , 2021, 6, 2292-2304.	0.8	96
12	Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. <i>American Journal of Kidney Diseases</i> , 2001, 38, S51-S56.	1.9	85
13	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2018, 93, 1281-1292.	5.2	69
14	Lipid, blood pressure and kidney update 2013. <i>International Urology and Nephrology</i> , 2014, 46, 947-961.	1.4	60
15	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1027-1036.	5.2	60
16	A Picture Is Worth a Thousand Views: A Triple Crossover Trial of Visual Abstracts to Examine Their Impact on Research Dissemination. <i>Journal of Medical Internet Research</i> , 2020, 22, e22327.	4.3	52
17	Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 41-49.	1.4	50
18	Improving Care Coordination Between Nephrology and Primary Care: A Quality Improvement Initiative Using the Renal Physicians Association Toolkit. <i>American Journal of Kidney Diseases</i> , 2015, 65, 67-79.	1.9	45

#	ARTICLE	IF	CITATIONS
19	Cardiovascular disease and chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 403-413.	1.1	44
20	Urinary tract infections. <i>Disease-a-Month</i> , 2015, 61, 45-59.	1.1	40
21	Hypertension and chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 387-395.	1.1	37
22	Abdominal compartment syndrome. <i>Disease-a-Month</i> , 2019, 65, 5-19.	1.1	36
23	Racial differences in potassium disposal. <i>Kidney International</i> , 2004, 66, 1076-1081.	5.2	26
24	Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 51-63.	1.4	22
25	<i>Pasteurella multocida</i> Peritonitis Another Risk of Animal-Assisted Therapy. <i>Infection Control and Hospital Epidemiology</i> , 2004, 25, 5-6.	1.8	20
26	NephMadness 2015: Nephrology as a Cornerstone of Medicine. <i>American Journal of Kidney Diseases</i> , 2015, 65, 375-377.	1.9	20
27	Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 515-529.	3.1	18
28	Anatomic and Physiologic Changes of the Aging Kidney. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 325-329.	2.6	17
29	Quantifying the Twitter Influence of Third Party Commercial Entities versus Healthcare Providers in Thirteen Medical Conferences from 2011 to 2013. <i>PLoS ONE</i> , 2016, 11, e0162376.	2.5	17
30	Diabetes and chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 378-386.	1.1	16
31	Multiple myeloma. <i>Disease-a-Month</i> , 2014, 60, 483-488.	1.1	15
32	Portal hypertension: Etiology, evaluation, and management. <i>Disease-a-Month</i> , 2016, 62, 411-426.	1.1	15
33	Anemia of chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 421-424.	1.1	13
34	Effects of staged versus ad hoc percutaneous coronary interventions on renal function—Is there a benefit to staging?. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 344-348.	0.8	13
35	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. <i>Postgraduate Medicine</i> , 2023, 135, 224-233.	2.0	13
36	Treatment Options for End Stage Renal Disease. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, 407-432.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Thrombotic thrombocytopenic purpura. Disease-a-Month, 2014, 60, 500-504.	1.1	12
38	Chronic kidney disease. Disease-a-Month, 2015, 61, 374-377.	1.1	12
39	Hepatorenal syndrome. Disease-a-Month, 2016, 62, 364-375.	1.1	12
40	Twitter-Based Journal Clubs: Additional Facts and Clarifications. Journal of Medical Internet Research, 2015, 17, e216.	4.3	12
41	Approach to the Patient with Renal Disease. Primary Care - Clinics in Office Practice, 2008, 35, 183-194.	1.6	9
42	Sickle cell nephropathy. Disease-a-Month, 2014, 60, 494-499.	1.1	9
43	Parameters Used to Discontinue Dialysis in Acute Kidney Injury Recovery: A Survey of United States Nephrologists. Nephron, 2015, 130, 41-47.	1.8	9
44	Cardio-Renal Syndrome: A double edged sword. Disease-a-Month, 2017, 63, 92-100.	1.1	8
45	Nephroendocrinology: When endocrinology meets nephrology. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 1-3.	5.7	7
46	Renal LECT2 amyloidosis: a newly described disorder gaining greater recognition. Clinical Nephrology, 2015, 84 (2015), 236-240.	0.7	7
47	Renal amyloidosis. Disease-a-Month, 2014, 60, 489-493.	1.1	6
48	Clinical hypertension: Blood pressure variability. Disease-a-Month, 2018, 64, 5-13.	1.1	6
49	Renal complications during pregnancy: In the hypertension spectrum. Disease-a-Month, 2019, 65, 25-44.	1.1	6
50	Gastrointestinal and renal excretion of potassium in Africanâ€“Americans and White Americans. Journal of Hypertension, 2012, 30, 2373-2377.	0.5	5
51	Mineral metabolism in chronic kidney disease. Disease-a-Month, 2015, 61, 425-433.	1.1	5
52	Practice patterns in transitioning patients from chronic kidney disease to dialysis: a survey of United States nephrologists. BMC Nephrology, 2018, 19, 147.	1.8	5
53	PICC line management among patients with chronic kidney disease. Journal of Vascular Access, 2021, , 112972982110258.	0.9	5
54	HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs, 2013, 13, 385-398.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Dyslipidemia in chronic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 396-402.	1.1	4
56	Autosomal dominant polycystic kidney disease. <i>Disease-a-Month</i> , 2015, 61, 442-447.	1.1	4
57	Are restless legs syndrome, pruritus or hiccoughs surrogates for inadequate dialysis?. <i>Seminars in Dialysis</i> , 2011, 24, 406-407.	1.3	3
58	Kidney transplantation for the primary care provider. <i>Disease-a-Month</i> , 2020, 66, 100869.	1.1	3
59	Lessons learnt and future directions in managing dialysis access during the COVID 19 pandemic: Patient and provider experience in the United States. <i>Journal of Vascular Access</i> , 2023, 24, 213-221.	0.9	3
60	Treatment of renal osteodystrophy. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2007, 5, 27-38.	0.8	2
61	Statin treatment in patients with elevated liver enzymes: Pitch to proceed. <i>Journal of Clinical Lipidology</i> , 2012, 6, 310-311.	1.5	2
62	Diagnosis of renal osteodystrophy. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2007, 5, 21-26.	0.8	1
63	Tissue plasminogen activator infusion as a treatment for hemodialysis catheter dysfunction. <i>Dialysis and Transplantation</i> , 2010, 39, 97-99.	0.2	1
64	Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?. <i>Current Hypertension Reports</i> , 2011, 13, 386-395.	3.5	1
65	ASTâ€120 for preventing progression of chronic kidney disease: What can we conclude from the available evidence?. <i>Dialysis and Transplantation</i> , 2011, 40, 194-195.	0.2	1
66	Nephrolithiasis for the primary care physician. <i>Disease-a-Month</i> , 2015, 61, 434-441.	1.1	1
67	Diagnosis 101: diabetic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1797-1799.	2.9	1
68	Clinical Presentation. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2004, 2, 209-216.	0.8	0
69	Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy. <i>Evidence-Based Medicine</i> , 2005, 10, 77-77.	0.6	0
70	Definition and classification of renal osteodystrophy. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2007, 5, 3-9.	0.8	0
71	Preface. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, ix-xi.	1.6	0
72	Preface. <i>Primary Care - Clinics in Office Practice</i> , 2008, 35, xi-xiii.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Preface. Clinics in Geriatric Medicine, 2009, 25, xi-xiii.	2.6	0
74	Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology, 2011, 5, 251-260.	1.5	0
75	Clinical Presentation of Nephrolithiasis. Clinical Reviews in Bone and Mineral Metabolism, 2011, 9, 181-186.	0.8	0
76	Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis and Transplantation, 2011, 40, 148-151.	0.2	0
77	Chronic Kidney Disease—Mineral Bone Disorder: New Understandings of an Old Disease. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 117-118.	0.8	0
78	Preface. Clinics in Geriatric Medicine, 2013, 29, ix-x.	2.6	0
79	The Clinical Relevance and Management of High-Flow Arteriovenous Access. Advances in Chronic Kidney Disease, 2020, 27, 214-218.	1.4	0
80	Optimizing Renin-Angiotensin System Inhibitor Use in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, , CJN.12950921.	4.5	0
81	Blood Pressure Management in the Patient with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 308-310.	4.5	0